SCHEMBL4821755

SCHEMBL4821755

Cc1ccc(C)c(O[Sc])c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 5/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP2C9 P11712 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 2/20 0.39
TTR P02766 1/20 0.39
CYP2C8 P10632 1/20 0.39
CHRM1 P11229 1/20 0.39
ADRA1A P35348 1/20 0.39
PPARG P37231 1/20 0.39
HTR2B P41595 1/20 0.39
PPARA Q07869 1/20 0.39
SLCO1B3 Q9NPD5 1/20 0.39
CISD1 Q9NZ45 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4817852 0.80 ACHE (0.46) ACHETSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL3278966 0.79 ACHE (0.50) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL30167567 0.77 ACHE (0.68) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL92174 0.77 ACHE (0.68) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL7923034 0.75 ACHE (0.46) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL3288769 0.75 ACHE (0.46) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL14521443 0.75 ACHE (0.46) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL4813842 0.75 ACHE (0.46) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL1047290 0.75 ACHE (0.46) ACHETSHRTDP1ALDH1A1CYP2C9
SCHEMBL11681222 0.75 ALDH1A1 (0.48) ACHETSHRTDP1ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337536-B1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEM PATENTS INC (US) 2012-09-12 EP disclosed
US-7390861-B2 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-06-24 US disclosed
US-20040033891-A1 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. 2004-02-19 US disclosed
EP-1337536-A1 CATIONIC GROUP-3 CATALYST SYSTEM ExxonMobil Chemical Patents Inc. (US) 2003-08-27 EP disclosed
WO-2002032909-A1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033891-A1 Cationic group-3 catalyst system COG3, ORC3, LIG3 ACHE 2631/4885TSHR 3172/4885TDP1 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.